🧫
Amyloid plaque load analysis in triple-mutant mouse brains
active
experiment
Created: 2026-04-10T22:32:02
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-4c97be59-973e-4997-bca9-8c28a6affaa8
🧫 Experiment Protocol
ExploratoryAlzheimer's diseaseSt8sia1APP/PSEN1/GD3S-/- triple-transgenic mouse brainsproposed
Brain tissue from APP/PSEN1/GD3S-/- triple-mutant mice was examined for amyloid-beta plaque formation and associated neuropathology. The analysis included assessment of both aggregated and unaggregated Abeta levels using histological and biochemical methods. Brain sections were processed for amyloid plaque visualization and quantification, comparing plaque burden between triple-mutant mice and APP/PSEN1 control mice. The study revealed that elimination of GD3S resulted in almost complete elimination of Abeta aggregation and associated neurodegeneration, providing neuropathological evidence supporting the behavioral improvements observed in these mice.
PRIMARY OUTCOME
amyloid plaque load reduction
EXPECTED OUTCOMES
1. The intervention targeting St8sia1 shifts amyloid plaque load reduction in the predicted direction relative to the matched control arm.
2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (amyloid plaque load reduction) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
- The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
- Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish APP/PSEN1/GD3S-/- triple-transgenic mouse brains cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for St8sia1, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure amyloid plaque load reduction together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Brain tissue from APP/PSEN1/GD3S-/- triple-mutant mice was examined for amyloid-beta plaque formation and associated neuropathology. The analysis included assessment of both aggregated and unaggregated Abeta levels using histological and biochemical methods. B
LINKED HYPOTHESES
Source: PMID 18258340 ↗
🧫 Experiment Extras
PATHWAY
amyloid aggregation and ganglioside interaction pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.